OJ, I don’t disagree with your statement. But the Covid vaccine front runners is where the money bets (stock buying) are. And until the front runners fail, which I believe they will (because they are based on mRNA), any GNBT/NGIO Covid vaccine CCs/PRs will not attract enough long term investors to significantly move the share price. And yes, the company must continue to work on the Ii-key Complete Vaccine, so when the leaders fall down, GNBT/NGIO will be there to grab the “flag” and complete the ”marathon” with a real vaccine that works.